
    
      Study visit times will correspond with standard follow-up evaluations for the patient's
      malignant glioma.

      Study visits will occur at baseline (Week 0); Week 7, which is when patients stop their use
      of study drug and their first round of external beam radiation therapy and temozolomide; and
      at Weeks 10, 18, and 34.

      The Week 7 evaluation will include: neuropsychological exam, Psychosocial Questionnaires, and
      questions about the patient's medications and health.

      The Week 10 and 18 evaluations will include: vital sign measurements, Karnofsky Performance
      status rating, neurological and neuropsychological exams, psychosocial questionnaires, an
      Magnetic Resonance Imaging (MRI) of the patient's brain, and questions about their
      medications and health.

      The Week 34 evaluation will include: vital sign measurements, Karnofsky Performance status
      rating, neurological and neuropsychological exams, psychosocial questionnaires, and questions
      about the patient's medications and health.
    
  